Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Stephanie Elisabeth Combs

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6934-2864; OpenAlex author ID A5061037633. Sources: OpenAlex.

Their work

Papers
32 (first author 2, last author 18)
Trials
0
Grants
0
Labs led
2
Collaborators
49
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 9 papers · 2014: 3 papers · 2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers

Papers 32

  1. Development of a translational radiobiology platform using pancreatic cancer patient-derived organoids for personalized radiation oncology. Co-author DOI 10.1016/j.tranon.2025.102535↗
  2. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41551-024-01273-9↗
  3. Identification of the unfolded protein response pathway as target for radiosensitization in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2023.110059↗
  4. Comparison of 3 Positioning Techniques for Fractionated High-precision Radiotherapy in an Orthotopic Mouse Model of Pancreatic Cancer. Co-author DOI 10.30802/aalas-cm-22-000060↗
  5. Impact of DNA repair and reactive oxygen species levels on radioresistance in pancreatic cancer. Last author DOI 10.1016/j.radonc.2021.03.038↗
  6. Modification of radiosensitivity by Curcumin in human pancreatic cancer cell lines. Last author DOI 10.1038/s41598-020-60765-1↗
  7. Radiosensitization by Kinase Inhibition Revealed by Phosphoproteomic Analysis of Pancreatic Cancer Cells. Co-author DOI 10.1074/mcp.ra120.002046↗
  8. The Emerging Role of miRNAs for the Radiation Treatment of Pancreatic Cancer. Last author DOI 10.3390/cancers12123703↗
  9. Continued Weight Loss and Sarcopenia Predict Poor Outcomes in Locally Advanced Pancreatic Cancer Treated with Chemoradiation. Last author DOI 10.3390/cancers11050709↗
  10. Cachectic Body Composition and Inflammatory Markers Portend a Poor Prognosis in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation. Last author DOI 10.3390/cancers11111655↗
  11. Essential role of radiation therapy for the treatment of pancreatic cancer : Novel study concepts and established treatment recommendations. Last author DOI 10.1007/s00066-017-1227-5↗
  12. Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both? Last author DOI 10.1186/s13014-017-0945-2↗
  13. Changes in Gross Tumor Volume and Organ Motion Analysis During Neoadjuvant Radiochemotherapy in Patients With Locally Advanced Pancreatic Cancer Using an In-Ho… Last author DOI 10.1177/1533034615577515↗
  14. Optimization of Carbon Ion Treatment Plans by Integrating Tissue Specific α/β-Values for Patients with Non-Resectable Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0164473↗
  15. Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors. Co-author DOI 10.1007/s00423-015-1309-8↗
  16. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. Last author DOI 10.1186/s12957-015-0560-3↗
  17. Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer. Last author DOI 10.1186/s13014-015-0538-x↗
  18. [Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP)]. Last author DOI 10.1007/s00066-013-0533-9↗
  19. Palliative radiation therapy in patients with metastasized pancreatic cancer - description of a rare patient group. Last author DOI 10.1186/2047-783x-19-24↗
  20. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer. Co-author DOI 10.1245/s10434-014-3607-8↗
  21. [Resection plus adjuvant chemotherapy improves survival in advanced pancreatic adenocarcinoma]. Co-author DOI 10.1007/s00066-012-0268-z↗
  22. Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comp… Co-author DOI 10.1007/s00066-013-0391-5↗
  23. Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer. Last author DOI 10.1007/s00066-013-0393-3↗
  24. Chemoradiotherapy for locally advanced pancreatic cancer. First author DOI 10.1016/s1470-2045(13)70091-3↗
  25. Advanced-stage pancreatic cancer: therapy options. First author DOI 10.1038/nrclinonc.2013.66↗
  26. In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines. Last author DOI 10.1093/jrr/rrt052↗
  27. Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial. Co-author DOI 10.1186/1471-2407-13-419↗
  28. Development and validation of automatic tools for interactive recurrence analysis in radiation therapy: optimization of treatment algorithms for locally advanc… Last author DOI 10.1186/1748-717x-8-138↗
  29. Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection. Last author DOI 10.1186/1748-717x-8-27↗
  30. [Database supported electronic retrospective analyses in radiation oncology: establishing a workflow using the example of pancreatic cancer]. Last author DOI 10.1007/s00066-012-0214-0↗
  31. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Last author DOI 10.1186/1748-717x-7-28↗
  32. [Strategies for preoperative downsizing in patients with local nonresectable pancreatic cancer]. Co-author DOI 10.1007/s00104-011-2129-1↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sophie Dobiasch · 9 shared papers, 2018–2025 · strength 1.44
  2. Jürgen Debus · 17 shared papers, 2011–2019 · strength 0.86
  3. Roland Michael Schmid · 5 shared papers, 2020–2025 · strength 0.84
  4. Daniel Habermehl · 16 shared papers, 2011–2017 · strength 0.74
  5. Günter Schneider · 4 shared papers, 2020–2025 · strength 0.63
  6. Jens Werner · 10 shared papers, 2011–2015 · strength 0.44
  7. Christian Schneeweis · 2 shared papers, 2024–2025 · strength 0.40
  8. Lily Nguyen · 3 shared papers, 2020–2021 · strength 0.38
  9. Maximilian Reichert · 2 shared papers, 2025 · strength 0.36
  10. Markus Wolfgang Büchler · 9 shared papers, 2011–2015 · strength 0.36
  11. Patrick Naumann · 4 shared papers, 2013–2019 · strength 0.31
  12. Thilo Hackert · 3 shared papers, 2013–2019 · strength 0.26
  13. Constantin Dreher · 4 shared papers, 2013–2017 · strength 0.24
  14. Oliver Jäkel · 4 shared papers, 2013–2017 · strength 0.24
  15. Jana Kern · 1 shared paper, 2024 · strength 0.24
  16. Kerstin Anne Kessel · 6 shared papers, 2012–2016 · strength 0.24
  17. Jan J. Wilkens · 1 shared paper, 2022 · strength 0.22
  18. S. Kampfer · 1 shared paper, 2022 · strength 0.22
  19. Wilko Weichert · 1 shared paper, 2025 · strength 0.21
  20. H. Carlo Maurer · 1 shared paper, 2025 · strength 0.21
  21. Felix Orben · 1 shared paper, 2025 · strength 0.21
  22. Christopher Keßler · 1 shared paper, 2025 · strength 0.21
  23. İhsan Ekin Demir · 1 shared paper, 2025 · strength 0.21
  24. Dirk Jäger · 4 shared papers, 2013–2015 · strength 0.16
  25. Katja Peschke · 1 shared paper, 2025 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.